Synthetic versus natural curcumin: bioequivalence in an in vitro oral mucositis model

BMC Complementary and Alternative Medicine

Christoph Aebi²  Rolf Troller²  Jeannette Goette¹  Sonja C Lüer³ 

[1] Institute of Hospital Pharmacy, University of Bern, Inselspital, Bern CH-3010, Switzerland;Institute for Infectious Diseases, University of Bern, Inselspital, Bern CH-3010, Switzerland;Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Bern, Inselspital, Bern CH-3010, Switzerland

关键词: Chemotherapy;    Cancer;    Mucositis;    Bioequivalence;    Synthetic;    Curcumin;   

Others  :  1220268
DOI  :  10.1186/1472-6882-14-53

 received in 2013-06-01, accepted in 2014-01-30,  发布年份 2014

【 摘 要 】

Background

Curcumin (CUR) is a dietary spice and food colorant (E100). Its potent anti-inflammatory activity by inhibiting the activation of Nuclear Factor-κB is well established.

Methods

The aim of this study was to compare natural purified CUR (nCUR) with synthetically manufactured CUR (sCUR) with respect to their capacity to inhibit detrimental effects in an in vitro model of oral mucositis. The hypothesis was to demonstrate bioequivalence of nCUR and sCUR.

Results

The purity of sCUR was HPLC-confirmed. Adherence and invasion assays for bacteria to human pharyngeal epithelial cells demonstrated equivalence of nCUR and sCUR. Standard assays also demonstrated an identical inhibitory effect on pro-inflammatory cytokine/chemokine secretion (e.g., interleukin-8, interleukin-6) by Detroit pharyngeal cells exposed to bacterial stimuli. There was bioequivalence of sCUR and nCUR with respect to their antibacterial effects against various pharyngeal species.

Conclusion

nCUR and sCUR are equipotent in in vitro assays mimicking aspects of oral mucositis. The advantages of sCUR include that it is odorless and tasteless, more easily soluble in DMSO, and that it is a single, highly purified molecule, lacking the batch-to-batch variation of CUR content in nCUR. sCUR is a promising agent for the development of an oral anti-mucositis agent.

【 授权许可】

   
2014 Lüer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gupta SC, Patchva S, Koh W, Aggarwal BB: Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012, 39:283-299.
• [2]Tennant DR: Screening potential intakes of colour additives used in non-alcoholic beverages. Food Chem Toxicol: an International Journal Published for the British Industrial Biological Research Association 2008, 46:1985-1993.
• [3]Aggarwal BB, Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94.
• [4]Lüer S, Troller R, Jetter M, Spaniol V, Aebi C: Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis? Support Care Cancer 2009, 19:799-806.
• [5]Lüer S, Troller R, Aebi C: Antibacterial and antiinflammatory kinetics of curcumin as a potential antimucositis agent in cancer patients. Nutr Cancer 2012, 64:975-981.
• [6]Helminen ME, Maciver I, Paris M, et al.: A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo. J Infect Dis 1993, 168:1194-1201.
• [7]Aebi C, Lafontaine ER, Cope LD, et al.: Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E. Infect Immun 1998, 66:3113-3119.
• [8]Spaniol V, Heiniger N, Troller R, Aebi C: Outer membrane protein UspA1 and lipooligosaccharide are involved in invasion of human epithelial cells by Moraxella catarrhalis. Microbes Infect 2008, 10:3-11.
• [9]Aggarwal BB, Harikumar KBM: Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59.
• [10]Zheng XH, Shao YX, Li Z, et al.: Quantitative structure-retention relationship of curcumin and its analogues. J Sep Sci 2012, 35:505-512.
• [11]Alam S, Panda JJ, Chauhan VS: Novel dipeptide nanoparticles for effective curcumin delivery. Int J Nanomedicine 2012, 7:4207-4221.
• [12]Esatbeyoglu T, Huebbe P, Ernst IM, et al.: Curcumin – from molecule to biological function. Angew Chem Int Ed Engl 2012, 51:5308-5332.
• [13]Zhu S, Moore TW, Lin X, et al.: Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol 2012, 4:633-640.
• [14]Yao JW, Lin F, Tao T, Lin CJ: Affinity interactions between natural pigments and human whole saliva. Arch Oral Biol 2011, 56:285-293.
• [15]Song J, Choi B, Jin EJ, Yoon Y: Curcumin suppresses Streptococcus mutans adherence to human tooth surfaces and extracellular matrix proteins. Eur J Clin Microbiol Infect Dis 2012, 31:1347-1352.
• [16]Garcia-Gomes AS, Curvelo JA, Soares RM, Ferreira-Pereira A: Curcumin acts synergistically with fluconazole to sensitize a clinical isolate of Candida albicans showing a MDR phenotype. Med Mycol 2012, 50:26-32.
• [17]De R, Kundu P, Swarnakar S, Ramamurthy T, et al.: Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 2009, 53:1592-1597.
• [18]Svanborg C, Hedlund M, Connell H, et al.: Bacterial adherence and mucosal cytokine responses. Receptors and transmembrane signaling. Ann N Y Acad Sci 1996, 797:177-190.
• [19]Hauf N, Chakraborty T: Suppression of NF-kappa B activation and proinflammatory cytokine expression by Shiga toxin-producing Escherichia coli. J Immunol 2003, 170:2074-2082.
• [20]Van‘t Land B, Blijlevens NM, Marteijn J, et al.: Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 2004, 18:276-284.
• [21]Authority EFS: Scientific Opinion on the re-evaluation of curcumin (E100) as a food additive. EFSA J 2010, 8:1679-1725.